akkaraju srinivas  the wall street transcript srinivas akkaraju srinivas akkaraju joined the life sciences team in the healthcare group at jp morgan partners llc in april  from october  to april  he was in the business and corporate development group at genentech inc most recently as senior manager there dr akkaraju was responsible for worldwide partnering activities including technology access deals inlicensing of early and latestage therapeutics and outlicensing of genentech development projects in addition to his business development role he also served for the last year as project team leader for one of genentech’s clinical development products during this time dr akkaraju was also a founding member of biostreet an online marketplace for biotech opportunities prior to joining genentech in  dr akkaraju was a graduate student at stanford university where he earned his md and phd in immunology dr akkaraju earned his undergraduate degrees in biochemistry and computer science from rice university in  related interviewsinvesting in biotechnology srinivas akkaraju  jp morgan partnersmay  therapeuticfocused biotechnology srinivas akkaraju  jp morgan parters llcmay   cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july   in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google syros appoints srinivas akkaraju to its board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street syros appoints srinivas akkaraju to its board of directors business wire jun    am edt syros pharmaceuticals nasdaqsyrs a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of diseasedriving genes today announced the appointment of srinivas akkaraju md phd to the companys board of directors srini is a recognized leader who brings a unique strategic perspective combining deep scientific knowledge with strong business acumen to help innovative biotechnology companies create value for patients and shareholders said nancy simonian md chief executive officer of syros his experience and insights will be tremendous assets to syros as we continue to evolve into a fully integrated biopharmaceutical company driven to delivering medicines that control the expression of diseasedriving genes to provide a profound and durable benefit for patients we are thrilled to welcome srini to our board dr akkaraju has nearly  years of investment and operational experience in the life sciences sector he is a founder and managing general partner at samsara biocapital prior to founding samsara biocapital he served as a general partner of sofinnova ventures from april  to june  managing director of new leaf venture partners from january  to april  and managing director of panorama capital a private equity firm that he helped found from september  to december  before cofounding panorama capital he was a partner at jp morgan partners and earlier in his career he was in business and corporate development at genentech now a wholly owned member of the roche group dr akkaraju currently serves as chairman of the board of versartis and as a director of intercept pharmaceuticals seattle genetics and atyr pharma previously he served on the boards of barrier therapeutics eyetech pharmaceuticals zs pharma synageva biopharma corp and amarin corp dr akkaraju received an md and a phd in immunology from stanford university and undergraduate degrees in biochemistry and computer science from rice university trending billionaire mark cuban the rise of technology will cause a lot of unemployment alphabet has one business that could be worth  of the company jim cramer explains trump just resurrected the ugly practice known as civil forfeiture for no reason starbucks has an alarming problem that even its fans must admit has to be fixed  and soon chipotle is doomed unless it takes this one dramatic measure advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers akkaraju srinivas form  insider trading history  insider insights insider data searchcompliance searchprospect searchmanage portfoliosnew portfoliomanage screensnew screen home about faq contact media mentions money management subscribe   search free insider data latest insider filings top  searches portfolio alerts top trades email special screens reports subscription insider data insider filing search prospect search insider special screens insider portfolio alerts subscribe to data module insider newsletter get latest newsletter subscribe to newsletter subscriber sign in preprogrammed screens preprogrammed searches saved client screens saved client searches saved client dossiers subscribe now sign in search by ticker search by filer name search by company name search by input date transaction types  b  ab  jb  ob  oe  oe  s  as  js  os  os    jb  js reduced version of subscription insider search check all filing types uncheck all filing types remove the noise free insider products insider portfolio alerts free real time insider alerts top trade alerts free insider trades intraday special screens report free insider special screens report our input date search is an excellent tool to examine the latest insider trades for new long and short investment ideas but it is only available to paid subscribers click here to subscribe close window feature available to paying subscribers only subscriber output is also not separated on different pages so that print outs and excel downloads contain all of a searchs information click here to subscribe close window detailed insider history forakkaraju srinivas click column headers to sort  view form insider statistics t n h m s insider title company name ticker trans type dollar value shares traded trans date from trans date to trans price from trans price to total holdings delta  owned owned other info sic code sic sector sic industry sic subindustry input date        dir intercept pharmaceuticals inc icpt jb         d r  manufacturing chemicals and allied products pharmaceutical preparations    pm        dir syros pharmaceuticals inc syrs          i   manufacturing chemicals and allied products pharmaceutical preparations    pm        dir versartis inc vsar jb         d r  manufacturing chemicals and allied products pharmaceutical preparations    pm        dir seattle genetics inc wa sgen jb         d r  manufacturing chemicals and allied products biological products no disgnostic substances    pm  y dir versartis inc vsar jb        new i   manufacturing chemicals and allied products pharmaceutical preparations    pm  y dir versartis inc vsar jb        new i   manufacturing chemicals and allied products pharmaceutical preparations    pm        dir intercept pharmaceuticals inc icpt jb         d r  manufacturing chemicals and allied products pharmaceutical preparations    pm        dir versartis inc vsar jb         d r  manufacturing chemicals and allied products pharmaceutical preparations    pm        dir seattle genetics inc wa sgen jb         d r  manufacturing chemicals and allied products biological products no disgnostic substances    pm  y dir intercept pharmaceuticals inc icpt ob         d   manufacturing chemicals and allied products pharmaceutical preparations    pm        dir zs pharma inc zsph js        all d r  manufacturing chemicals and allied products pharmaceutical preparations    pm        dir intercept pharmaceuticals inc icpt jb         d r  manufacturing chemicals and allied products pharmaceutical preparations    pm  y dir intercept pharmaceuticals inc icpt ob         d   manufacturing chemicals and allied products pharmaceutical preparations    am amazoncom widgets subscribe search screens alerts newsletter money management free stuff home about faq contact disclaimer  terms of use privacy media mentions transaction codes   insiderinsightscom   akkaraju srinivas  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address co intercept pharmaceuticals inc  hudson yards floor  new york ny   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg pretpwinssretswins filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  vsarversartis inchealthdrugpharmaceutical preparationsakkaraju srinivascadpi  vsarversartis incdehealthdrugpharmaceutical preparationsakkaraju srinivascadpi  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  lifeatyr pharma incdehealthbioprdbiological products no diagakkaraju srinivascadhformer pdi  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydpdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  vsarversartis incdehealthdrugpharmaceutical preparationsakkaraju srinivascadtpdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydsdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydsd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivaswadmdd  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivaswadsdd  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivaswadmdd  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivaswadsdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdnewd  icptintercept pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydpnewi  gevasynageva biopharma corpdehealthbioprdbiological products no diagakkaraju srinivascahformer dsmi  gevasynageva biopharma corpdehealthbioprdbiological products no diagakkaraju srinivascadsi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivaswadmdd  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadpd  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadpnewd  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsadi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsadi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  btrxbarrier therapeutics incdehealthdrugpharmaceutical preparationsakkaraju srinivascadsai  sgenseattle genetics inc wadehealthbioprdbiological products no diagakkaraju srinivascadsdi  eyeteyetech pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydmdi  btrxbarrier therapeutics incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydsi  btrxbarrier therapeutics incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydpi  btrxbarrier therapeutics incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydsi  eyeteyetech pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydsdi  eyeteyetech pharmaceuticals incdehealthdrugpharmaceutical preparationsakkaraju srinivasnydsdi dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved syros pharmaceuticals srinivas akkaraju your browser is blocking javascript this might limit your experience on this website subscribe free newsletter breaking news on global pharmaceutical technology  manufacturing ingredients drug delivery processing regulatory  safety headlines ingredients drug delivery processing regulatory  safety video audio gallery internet live events site archive july  june  previous months hot topics bioavailability challenge globalisation lifecycle management mergers and acquisitions resource library apis active pharmaceutical ingredients delivery formulations delivery technologies excipients raw materials and intermediates packaging machinery  supplies processing equipment qaqc regulations tabletting coating  ancillary equipment resources all products supplier webinars videos  audio technical papers product brochures suppliers events all events shows  conferences other industry events on the road cphi worldwide paris  aaps  san diego technopharm  powtech  nuremberg germany interphex  aaps  in san antonio cphi  in frankfurt interphex  in new york aaps  in chicago cphi  in madrid achema  in frankfurt interphex  in new york interphex  in new york aaps  in new orleans related sites outsourcingpharmacomcontract research manufacturing  clinical trials biopharmareportercombiopharmaceutical development  manufacturing headlines  regulatory  safety read more breaking news     text size print forward subscribe to our free newsletter subscribe syros pharmaceuticals srinivas akkaraju     massachusetts usbased syros pharmaceuticals has appointed srinivas akkaraju to the company’s board of directors the biopharmaceutical firm focuses on the understanding of the noncoding region of the genome to advance medicines that control expression of diseasedriving genesthe company is currently focused on cancer and immunemediated diseases and is advancing a growing pipeline of gene control medicinessyros spokesperson naomi aoki told inpharmatechnologist akkaraju’s businessfocused background will benefit the firm in strategic decision making“our goal is to leverage our leadership in gene control to build a fully integrated and enduring company by maximising the promise of our programmes and our platform across disease areas along the way there will be many key strategic decisions around our programs potential partnerships and financings” she said“srini brings a compelling strategic perspective combining deep scientific knowledge with strong business acumen he has a proven track record as an investor and a board member of helping innovative biotechnology companies create value for patients and shareholders and we believe his experience and expertise will be valuable in helping us navigate many of those important strategic decisions” aoki told usakkaraju received an md and phd in immunology from standford universityhe is founder and managing partner at samsara biocapital was a general partner of sofinnova ventures and managing director of new leaf venture partners and panorama capitalhe is chairman of the board at versartis and a director of intercept pharmaceuticals seattle genetics and atyr pharma ocugen daniel jorgensen syros pharmaceuticals srinivas akkaraju igbma ingrid schwarzenberger boyds elaine harper  jayne hunt dragonfly therapeutics nicolai wagtmann          all gallery pharma executives make a move recent appointments ocugen welcomes expfizer daniel jorgensen the igbma’s biosimilars committee gets a new chair and drug development consultants moving up in the world recent pharma appointments the us fda welcomes scott gottlieb to the helm actinium appoints adult leukaemia expert richard stone and hiring and firing feb  inpharmatechnologist presents this months roundup of who is moving where in the pharma industry hiring and firing jan  welcome to inpharmatechnologists monthly round up of whos been moving where in the smallmolecule manufacturing world the drug development in space how microgravity enables pharma eli lilly is conducting several experiments on the international space station iss us national laboratory over the most popular news merck unveils eu plant cuts and consolidation plan citing sigmas us strategymylans eu biosimilar ambition hit by gmp issues at biocon plantvaccine booster for france big pharma preparedus fda warns vista pharmaceuticals about telangana plant concerns raised about italy and greece as backdoors into the fmd protected meds markets key industry events   access all events listing our events shows  conferences products influence of different lubricants on tableting characteristics and dissolution behavior jrs pharma the solid dose latest news from colorcon colorcon inc increase tablet production with multitip tools i holland limited view all products todays headlines gsk says uk manufacturing cuts not brexit related the serialisation stragglers industry concern for complacency who prequalifies mylans india unit to supply tb drug api eu to probe if drug firms presubmission meetings sway ema approval decisions us fda reaffirms hold on oral proellex trials prompting repros rethink us fda warns opthalmic supplier tubilux about italian plant weekly  daily free newsletters inpharmatechnologistcomoutsourcingpharmacombiopharmareportercom pharmaceutical technology  daily pharmaceutical outsourcing  daily biopharmaceutical development  daily pharmaceutical technology  weekly pharmaceutical outsourcing  weekly biopharmaceutical development  weekly       apis active pharmaceutical ingredients analytical testing qc analytical technologies  services delivery formulations contract manufacturing biooutsourcing delivery technologies drug delivery formulation bioreactors excipients raw materials and intermediates fill  finish packaging cell lines processing equipment medical devices disposable manufacturing tech qaqc phase iii facilities regulations phase iiiiv fillfinish  packaging tabletting coating  ancillary equipment preclinical separation  purification   regulatory affairs     supply chain logistics   other newsletters pharma legislationpharma financeclinical researchdrug targeting and delivery subscribe to our free newslettersubscribe related sites from our team contract research manufacturing  clinical trials    biopharmaceutical development  manufacturing about us  site map  all sites  recommend this site  advertise  contact the editor  terms  conditions  privacy  cookie policy srinivas akkaraju turns over new leaf  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital srinivas akkaraju turns over new leaf january   by pehub administrator srinivas akkaraju has joined new leaf venture partners as a managing director and head of the firm’s west coast biopharma practice he previously was a cofounder and managing director of panorama capital press release new leaf venture partners nlv partners announced today the appointment of srinivas akkaraju md phd as managing director and lead of nlv partners’ west coast biopharmaceuticals practice dr akkaraju’s appointment is effective immediately   “dr akkaraju will be a tremendous addition to nlv partners and we are delighted to welcome him to the team” stated philippe chambon md phd managing director of nlv partners “we expect his broad network of contacts and extensive experience in the biopharma industry will prove invaluable for the firm and to our portfolio companies particularly on the west coast”   dr akkaraju commented “i am excited to join nlv partners the depth quality and cohesiveness of nlv partners attracted me to the firm and i look forward to the opportunity to continue developing as an investor in a dynamic and creative environment”   dr akkaraju brings over  years of experience in life sciences investing and business development prior to joining nlv partners dr akkaraju was a cofounder and managing director of panorama capital before forming panorama dr akkaraju served as partner of jp morgan partners llc where he was responsible for leading venture investing in biotech companies previously dr akkaraju held business and corporate development positions at genentech where he was responsible for worldwide partnering activities inlicensing of therapeutics and outlicensing of development projects in addition dr akkaraju was a founding member of biostreet an online marketplace for biotech opportunities   dr akkaraju currently serves on the board of directors of amarin corporation seattle genetics and pharmos corporation as well as several private companies he is the author of a number of peerreviewed articles including in science and nature he received ba degrees in both biochemistry and computer science from rice university and md and phd degrees in immunology from stanford university school of medicine   about nlv partners   nlv partners is a life sciencededicated venture capital firm with offices in menlo park and new york founded by an experienced team of venture capitalists with deep healthcare industry experience nlv partners invests primarily in companies focused on clinicalstage biopharmaceutical products earlystage medical devices and molecular diagnostics nlv partners manages over  billion of assets including nlvi nlvii and the healthcare technology portfolio of sprout group for further information visit the nlv partners website at wwwnlvpartnerscom take your pick buyouts delivers exclusive news and analysis about private equity deals fundraising topquartile managers and more get your free trial or subscribe now vc journal provides exclusive news and analysis about venture capital deals fundraising topquartile investors and more get your free trial or subscribe now sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts new oil and gas company native racks up  mln by iris dorbian bain capital double impact funds two companies by iris dorbian midocean to sell water pik for  bln by luisa beltran carlyle to invest in zerochaos by luisa beltran awake security nabs over  mln from greylock and bain capital ventures by iris dorbian thoma bravo to sell sparta systems to new mountain by iris dorbian the pe hub podcast episode two by staff report post capital sells bhs specialty chemicals by iris dorbian srinivas akkaraju managing director seattle genetics inc  spoke login register add company add person add topic login or home  people  srinivas akkaraju advanced search faq javascript is disabled bio edit srinivas akkaraju srinivas d managing director seattle genetics inc bothell wa find other people named srinivas akkaraju general info biological product except diagnostic manufacturing add tags— eg finance businessbusiness back to top srinivas akkarajumd phdhas served as a director of seattle genetics since july  dr akkaraju is a managing director at panorama capital previously he was with jp morgan partners serving as a principal starting in april  and becoming a partner in january  from october  to april  he was in business and corporate development at genentech inc most recently as senior manager prior to joining genentech dr akkaraju was a graduate student at stanford university where he earned his md and a phd in immunology he received his undergraduate degrees in biochemistry and computer science from rice university he is also a director of barrier therapeutics not who youre looking for find other srinivas akkarajus on spoke contact telephone email background report public records powered by digital info wwwseattlegeneticscom na na na na na na resume edit career seattle genetics inc managing director education edit add a degree— eg bachelors in business administration blogs by industry voices there are currently no blogs by industry voices achievements and recognition edit add an achievement andor recognition— eg man of the year forbes  notable links edit the links below are powered by bing search results click edit to customize videos edit add a videofrom youtube or vimeo executives  featured people at seattle genetics inc daniel hoth president todd simpson chief financial officer paul carter vice president eric dobmeier cbo clay siegall president and chief executive officer ken realmuto contract recruiter kirsten smith senior directorhuman resources created on jun   by spoke   edited on jun   by spoke   page completion  summary career websiteblog industry add a photo add  notable links add  achievements add education add a video add a social network view more view less share this page add page add company add person add topic copy this code to embed a widget div idspokerootdiv scriptfunctiond s id document script spokewidgetjsscript div classspokewidget datahostwwwspokecom datatypeperson dataidececfe datawidth dataheight datascrollno dataframebordernonediv div stylefontsize pta hrefhttpwwwspokecompeoplesrinivasakkarajuececfesrinivas akkarajua widget provided by a hrefhttpwwwspokecomspokeadiv public records our partner can help you find public records for srinivas more on some of spokes content providers become a spoke content provider learn more icpt srinivas akkaraju insider trades for intercept pharmaceuticals inc bulletin investor alert tokyo markets open in us market snapshot currencies commodities expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close intercept pharmaceuticals inc nasdaq icpt go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus intercept pharmaceuticals inc after hours  quotes are delayed by  min jul    pm icpt quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual srinivas akkaraju dr srini akkaraju md phd is general partner at sofinnova ventures inc he also serves on several boards prior to joining sofinnova ventures in  dr akkaraju was a managing director at new leaf venture partners prior to nlvp he was a cofounder and managing director at panorama capital before forming panorama he served as partner of jp morgan partners prior to jp morgan partners srini held business and corporate development positions at genentech dr akkaraju received ba degrees in both biochemistry and computer science from rice university and md and phd degrees in immunology from stanford university school of medicine transactions date shares transaction value     award at  per share      award at  per share      derivativenonderivative trans at  per share      award at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      acquisition at  per share      acquisition at  per share      acquisition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr mark e pruzanski president chief executive officer  director mr jerome b durso chief operating officer mr sandip s kapadia chief financial officer dr david a shapiro chief medical officer  executive vpdevelopment mr richard kim senior vice presidentcommercial head of us dr juan carlos lopeztalavera senior vice presidenthead medical affairs ms lisa bright presidentinternational dr rachel l mcminn chief business  strategy officer mr christopher frates media contact dr mark j vignola directorinvestor relations mr paolo fundarò chairman dr keith m gottesdiener independent director mr daniel mark bradbury independent director mr daniel g welch independent director mr gino santini independent director dr luca benatti independent director mr glenn p sblendorio independent director dr srinivas akkaraju independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pat least  dead after overheated tractortrailer found outside texas walmart p‘full transparency’ doesn’t mean what scaramucci apparently thinks it means pstocks brace for volatility in earnings deluge fed meeting looms pthe dark side of cruises pif you suddenly quit your job like sean spicer here’s what you should do next pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pnever ever say these things to a coworker pmy uncle with dementia needs longterm care — should i refinance his house pthis is the deadliest time of your life to put on weight p easily avoidable reasons why millennials can’t have nice things or save any money pwhy house prices in gay neighborhoods are soaring pnearly  of adults don’t have life insurance — these startups are trying to change that pmarie kondo says this one thing could be holding you back from falling in love pthis luxury credit card is only for truly big spenders phow elon musk and shorter commutes could transform people’s lives pbanks have raised creditcard interest rates — but not savings account rates pthe most expensive city in the world is not new york or san francisco p in  americans say they will die in debt pshopping at costco and  other things that prove rich people are cheap aheavy showers swamp new orleans street with rainwater loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice    forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied